

PRODUCT INFORMATION



Antisauvagine-30 (trifluoroacetate salt)

Item No. 34271

Formal Name:	D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-lysyl-L-methionyl-L-isoleucyl-L- α -glutamyl-L-isoleucyl-L- α -glutamyl-L-lysyl-L-glutamyl-L- α -glutamyl-L-lysyl-L- α -glutamyl-L-lysyl-L-glutamyl-L-glutamyl-L-alanyl-L-alanyl-L-asparagyl-L-asparagyl-L-arginyl-L-leucyl-L-leucyl-L-leucyl-L- α -aspartyl-L-threonyl-L-isoleucinamide, trifluoroacetate salt	H — D-Phe — His — Leu — Leu — Arg — Lys — Met — Ile — Glu — Ile — Glu — Lys — Gln — Glu — Lys — Glu — Lys — Gln — Gln — Ala — Ala — Asn — Asn — Arg — Leu — Leu — Leu — Asp — Thr — Ile — NH ₂ • XCF ₃ COOH
Synonyms:	AS30, D-FHLLRKMIEIEKNEKEKNNAANNRLLDIT-NH ₂ , [D-Phe ¹¹ , His ¹²]SvG ₁₁₋₄₀ , aSvG, aSvG-30	
MF:	C ₁₆₁ H ₂₇₄ N ₄₈ O ₄₆ S • XCF ₃ COOH	
FW:	3,650.3	
Purity:	≥95%	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Antisauvagine-30 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the antisauvagine-30 (trifluoroacetate salt) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Antisauvagine-30 is a peptide antagonist of corticotropin-releasing factor receptor 2 (CRF₂).^{1,2} It is selective for CRF_{2a} over CRF₁ (K_is = 1.75 and 915 nM, respectively for the human receptors).¹ Antisauvagine-30 (10 nM) inhibits sauvagine-induced cAMP production in HEK293 cells expressing mouse CRF_{2b}.² It prevents stress-induced contextual fear conditioning in mice.³ Antisauvagine-30 reduces vasoactive intestinal peptide-induced decreases in food intake in rats.⁴

References

1. Dautzenberg, F.M., Py-Lang, G., Higelin, J., *et al.* Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: Evidence for evolutionary differences. *J. Pharmacol. Exp. Ther.* **296**(1), 113-120 (2001).
2. Rühmann, A., Bonk, I., Lin, C.R., *et al.* Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2 β -selective antisauvagine-30. *Proc. Natl. Acad. Sci. USA* **95**(26), 15264-15269 (1998).
3. Sananbenesi, F., Fischer, A., Schrick, C., *et al.* Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: A possible link between stress and fear memory. *J. Neurosci.* **23**(36), 11436-11443 (2003).
4. Garnica-Siqueira, M.C., Martins, A.B., Zaia, D.A.M., *et al.* Corticotrophin-releasing factor mediates vasoactive intestinal peptide-induced hypophagia and changes in plasma parameters. *Horm. Behav.* **105**, 138-145 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM